Experimental Arthritis Drug Dropped After Trial Misses
Patients with psoriatic arthritis and axial spondyloarthritis will not see SPY072 advance in these conditions from this program.
Updated on Nov. 4, 2026 in Arthritis
Spyre Therapeutics has dropped development of its experimental drug SPY072 in rheumatic diseases after two Phase 2 sub-studies missed their primary endpoints in psoriatic arthritis and axial spondyloarthritis. The company is redirecting the drug into a combination trial with bimekizumab for hidradenitis suppurativa, a skin condition.
Why it matters
For people living with arthritis-related inflammatory conditions, the setback means SPY072 will not be available as a new option in these indications for the foreseeable future. The decision also shows how drug developers weigh modest trial signals against internal benchmarks before committing hundreds of millions of dollars to late-stage testing.
The RA sub-study enrolled 143 patients and used a randomized, placebo-controlled design, with the low dose meeting its primary endpoint while the high dose did not reach statistical significance. Spyre did not release response rates or effect sizes for the psoriatic arthritis and axial spondyloarthritis sub-studies, which also failed their primary endpoints.
The players
Spyre Therapeutics
A biotechnology company developing TL1A-targeting antibodies for inflammatory diseases including rheumatic conditions, ulcerative colitis, and hidradenitis suppurativa.
Merck
A global pharmaceutical company whose tulisokibart, a TL1A antibody, reported positive Phase 2b results in hidradenitis suppurativa in September 2026.
The details
SPY072 is engineered with half-life extension technology and formulated at high concentration so it can be given by subcutaneous injection on an infrequent maintenance schedule. It targets TL1A, a cytokine involved in inflammatory signaling. Spyre said the RA effect size did not meet its internal bar for prioritizing SPY072 as a monotherapy in that disease, leading it to shift the molecule toward combination testing.
Timeline
June 2026: Spyre completed enrollment in the SKYWAY RA, PsA, and axSpA sub-studies.
August 2026: RA sub-study topline results were reported with a mixed readout.
September 2026: Spyre began the Phase 2 SKYLIGHT trial combining SPY072 with bimekizumab.
November 3, 2026: Spyre reported third-quarter results disclosing the PsA and axSpA failures.
Late 2027 or early 2028: Week 16 SKYLIGHT results are planned.
Health Landscape
Anti-TL1A antibodies are being developed as a newer class of inflammatory-disease treatments alongside established biologics in rheumatology and dermatology. The mixed SPY072 results show that a mechanism can succeed in one inflammatory condition while struggling in another, which shapes how drug developers prioritize indications.
If you live with psoriatic arthritis or axial spondyloarthritis, SPY072 will not be a new option from this program in the near term, so your current treatment plan remains the relevant one. Anyone whose clinician has discussed emerging therapies may find it worth asking what is in the pipeline for their condition.
The takeaway
A failed sub-study does not always end a drug's story, since developers often test promising molecules in new combinations and new diseases. If you are tracking treatment options for inflammatory arthritis, it is worth discussing with your physician how pipeline results may or may not apply to your care.
What happens next
Week 16 results from the Phase 2 SKYLIGHT trial combining SPY072 with bimekizumab are planned for late 2027 or early 2028. Induction data from the Phase 2 SKYLINE ulcerative colitis trial are expected in the third quarter of 2027.
Further reading
Explore more on Arthritis developments and how new treatments are evaluated.
Source note: This article includes information reported by BioPharm International.
